UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 17, 2006
Acorda Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-50513 |
|
13-3831168 |
|
(State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
|
of incorporation) |
|
File Number) |
|
Identification No.) |
|
|
|
|
|
|
|
15 Skyline Drive, Hawthorne, NY |
|
10532 |
|
(Address of principal executive offices) |
|
(Zip Code) |
|
|
|
|
|
Registrant’s telephone number, including area code: (914) 347-4300 |
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On October 17, 2006, Acorda Therapeutics, Inc. issued a press release announcing the expansion of its sales force, which promotes Zanaflax CapsulesTM. A copy of the release is attached hereto as Exhibit 99.1 and incorporated by reference into this Item.
Also on October 17, 2006, Acorda gave notice to Innovex Inc. (“Innovex”) of termination of the parties’ contract sales force agreement. Acorda had engaged Innovex to provide six contract sales representatives on a part-time basis to promote Zanaflex Capsules™ to primary care physicians.
The information in this Item 8.01 of Form 8-K (including Exhibit 99.1) shall not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
99.1 Press Release dated October 17, 2006
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Acorda Therapeutics, Inc. |
|
|
|||
|
|
|
|
|
|
|
|
October 17, 2006 |
By |
|
/s/ Jane Wasman |
|
|
|
|
|
|
|
|
|
|
|
|
|
Name: Jane Wasman |
|
|
|
|
|
|
Title: Executive Vice President, General |
|
|
|
|
|
|
Counsel and Corporate Secretary |
|
|
2